miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

Por Jakob V Schou, Simona Rossi, Benny V Jensen, Dorte L Nielsen, Per Pfeiffer, Estrid Høgdall, Mette Yilmaz, Sabine Tejpar, Mauro Delorenzi, Mogens Kruhøffer, Julia S Johansen
Publicado em 2014-01-01